Then we disagree on the timeline and on the % of success. We agree on the buyout you are right that is most likely before it reaches the billion MC I suggested.
Look if the 6 super-responders in AD as shown in the PK/PD will be reproduced in the 300 trial, and there is not any reason that will not do so, Anavex will be the new SOC overtaking donepezil by many milestones!. Look donepezil was granted SOC 6 months! in its 12 months trial with absolute zero significant IMO. No its a 75% change Anavex will get SOC on AD in its next trial.
Market Data 
Markets 
